Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, January 19 '25)

Image
By G.M.

 


    J Infect

  1. NURMI V, Mayne R, Knight C, Almonacid-Mendoza HL, et al
    Individual patient and donor seroprofiles in convalescent plasma treatment of COVID-19 in REMAP-CAP clinical trial.
    J Infect. 2025 Jan 9:106412. doi: 10.1016/j.jinf.2025.106412.
    PubMed         Abstract available

  2. RJOOB K, Antonelli M, Murray B, Molteni E, et al
    Symptom Evolution in Individuals with Ongoing Symptomatic COVID-19 and Post COVID-19 Syndrome After SARS-CoV-2 Vaccination Versus Influenza Vaccination.
    J Infect. 2025 Jan 10:106406. doi: 10.1016/j.jinf.2024.106406.
    PubMed         Abstract available

  3. WENDEL-GARCIA PD, Ceccato A, Motos A, Franch-Llasat D, et al
    Empirical antibiotic therapy improves outcomes in mechanically ventilated patients with COVID-19: An emulated targeted trial within a prospective, multicentre cohort study.
    J Infect. 2025 Jan 13:106411. doi: 10.1016/j.jinf.2025.106411.
    PubMed         Abstract available

  4. ROMERO-RAMIREZ A, Somasundaran A, Kontogianni K, Parkes J, et al
    Evaluation of the diagnostic accuracy of Xpert(R) Mpox and STANDARD M10 MPX/OPX for the detection of monkeypox virus.
    J Infect. 2025 Jan 15:106413. doi: 10.1016/j.jinf.2025.106413.
    PubMed         Abstract available


    J Med Virol

  5. BIRD PW, Zolana B, Oladejo S, Gurung S, et al
    Changing Patterns of Seasonal Respiratory Virus Incidence (2018-2023) Pre- and Post-COVID-19, Leicester, UK.
    J Med Virol. 2025;97:e70148.
    PubMed        

  6. HUYGHE E, Abrams S, Andre E, Anseeuw K, et al
    Systematic Molecular Influenza A/B Screening Upon Hospital Admission in Belgium, January-April 2022: Positivity Ratios and Viral Loads According to Symptomatology, Age, and Vaccination Status.
    J Med Virol. 2025;97:e70167.
    PubMed         Abstract available

  7. SANCHEZ-SIMARRO A, Cuevas-Ferrando E, Fernandez-Soto D, Grau B, et al
    Estimating SARS-CoV-2 Omicron XBB.1.5 Spike-Directed Functional Antibody Levels From an Anti-Receptor Binding Domain Wuhan-Hu-1-Based Commercial Immunoassay Results.
    J Med Virol. 2025;97:e70130.
    PubMed         Abstract available

  8. AREVALO-HERRERA M, Rincon-Orozco B, Gonzalez-Escobar JM, Herrera-Arevalo SM, et al
    Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.
    J Med Virol. 2025;97:e70133.
    PubMed         Abstract available

  9. CHUA HK, Singh A, Wang Y, Goh YS, et al
    Defining the Critical Requisites for Accurate Simulation of SARS-CoV-2 Viral Dynamics: Patient Characteristics and Data Collection Protocol.
    J Med Virol. 2025;97:e70174.
    PubMed         Abstract available

  10. ZHOU X, Liu H, Yang S, Dong X, et al
    Rapid Generation of Reverse Genetics Systems for Coronavirus Research and High-Throughput Antiviral Screening Using Gibson DNA Assembly.
    J Med Virol. 2025;97:e70171.
    PubMed         Abstract available

  11. ALOSAIMI B, Awadalla M, Alturaiki W, Chen Z, et al
    A 10 Year Long-Lived Cellular and Humoral MERS-CoV Immunity Cross-Recognizing the Wild-Type and Variants of SARS-CoV-2: A Potential One-Way MERS-CoV Cross-Protection Toward a Pan-Coronavirus Vaccine.
    J Med Virol. 2025;97:e70071.
    PubMed         Abstract available

  12. SILVERIO BS, Guilardi MD, Martins JO, Duro RLS, et al
    Coronavirus Cryptic Landscape and Draft Genome of a Novel CoV Clade Related to MERS From Bats Circulating in Northeastern Brazil.
    J Med Virol. 2025;97:e70173.
    PubMed         Abstract available


    J Virol

  13. NAGHIBOSADAT M, Babuadze GG, Pei Y, Hurst J, et al
    Vaccination against SARS-CoV-2 provides low-level cross-protection against common cold coronaviruses in mouse and non-human primate animal models.
    J Virol. 2025 Jan 16:e0139024. doi: 10.1128/jvi.01390.
    PubMed         Abstract available

  14. CAI C, Pham TNQ, Adam D, Brochiero E, et al
    Sensing of SARS-CoV-2-infected cells by plasmacytoid dendritic cells is modulated via an interplay between CD54/ICAM-1 and CD11a/LFA-1 alpha(L) integrin.
    J Virol. 2025 Jan 13:e0123524. doi: 10.1128/jvi.01235.
    PubMed         Abstract available


    Lancet

  15. THORNTON J
    Every Story Matters: public voices in the COVID-19 Inquiry.
    Lancet. 2025 Jan 14:S0140-6736(25)00095-9. doi: 10.1016/S0140-6736(25)00095.
    PubMed        


    Lancet Infect Dis

  16. ALVES K, Kotloff K, McClelland RS, Kouassi A, et al
    Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study.
    Lancet Infect Dis. 2025 Jan 14:S1473-3099(24)00670.
    PubMed         Abstract available

  17. YADAV PD, Patil DY
    Interim analysis of SARS-CoV-2 vaccine NVX-CoV2601 as a heterologous booster dose.
    Lancet Infect Dis. 2025 Jan 14:S1473-3099(25)00005.
    PubMed        


    MMWR Morb Mortal Wkly Rep

  18. PAPA A, Barile JP, Jia H, Thompson WW, et al
    Gaps in Mental Health Care-Seeking Among Health Care Providers During the COVID-19 Pandemic - United States, September 2022-May 2023.
    MMWR Morb Mortal Wkly Rep. 2025;74:19-25.
    PubMed         Abstract available


    Science

  19. VAN KERKHOVE MD
    Don't pretend COVID-19 didn't happen.
    Science. 2025;387:229.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »